# UBS Group

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ubs-group
Canonical HTML page: https://getbiobrief.com/entity/ubs-group

## Timeline

- **2026-06-30**: Schikan sells 30,712 shares — Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
- **2026-06-29**: Schikan sells 6,888 shares — Director Johannes Gerardus Chri Schikan sold 6,888 shares at $35.05, totaling $241,424.
- **2026-06-16**: HC Wainwright reiterates buy rating — HC Wainwright reaffirmed its buy rating on Pharvaris shares.
- **2026-05-13**: UBS sets $74 price target — UBS Group issued a research note with a $74 price objective on Pharvaris.
- **2026-05-12**: Q1 earnings beat — Pharvaris reported Q1 EPS of -$0.70, beating the consensus estimate of -$0.82.
- **2026-04-21**: Weiss Ratings issues sell (d-) rating — Weiss Ratings reaffirmed a sell rating on Pharvaris shares, citing financial risks.
- **2026-04-07**: Wedbush raises price target to $42 — Wedbush lifted its price target on Pharvaris from $41 to $42 with an outperform rating.

## Recent coverage (3 stories)

### Halozyme's ENHANZE drives 47.7% revenue surge and FY26 EPS guidance 8% above Street
2026-08-12 02:48:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Full story: https://getbiobrief.com/story/halozyme-enhanze-partner-royalties-q2-2026-guidance

### Teva's $1.91-$2.11 EPS Outlook Misses as Biotech Investors Weigh Risk-Reward
2026-08-05 14:16:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Full story: https://getbiobrief.com/story/teva-fy2026-guidance-biotech

### $1.33M Insider Sale at Pharvaris: What It Means for HAE Drug Catalysts
2026-07-11 21:42:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Full story: https://getbiobrief.com/story/pharvaris-insider-sale-1.33m-hae-catalysts

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.